A open-label study of Entecavir in the patients with acute hepatitis B for preventing chronicity and aggravation

A open-label study of Entecavir in the patients with acute hepatitis B for preventing chronicity and aggravation - GLSG,2006,Acute hepatitis B

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000643

Enrollment

Registered

2013-10-01

Start date

2006-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute hepatitis B

Interventions

Entecavir

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Acute hepatitis B that has the possibility of chronicity and aggravation Acute hepatitis B (genotype A) no less than nineteen

Exclusion criteria

Exclusion criteria: Fulminant hepatitis During pregnancy and the possibility of pregnancy Participating in the other clinical trials

Design outcomes

Primary

Measure	Time frame
HBV-DNA	—

Secondary

Measure	Time frame
transaminase	—

Countries

Japan

Contacts

Public ContactKen Sato

Gunma University Graduate School of Medicine Department of Medicine and Molecular Science

satoken@showa.gunma-u.ac.jp027-220-8127

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026